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BACKGROUND AND PURPOSE: The purpose of the COMPLETE (International Acute Ischemic Stroke Registry With the Penumbra 
System Aspiration Including the 3D Revascularization Device) registry was to evaluate the generalizability of the safety and 
efficacy of the Penumbra System (Penumbra, Inc, Alameda) in a real-world setting.
METHODS: COMPLETE was a global, prospective, postmarket, multicenter registry. Patients with large vessel occlusion–
acute ischemic stroke who underwent mechanical thrombectomy using the Penumbra System with or without the 3D 
Revascularization Device as frontline approach were enrolled at 42 centers (29 United States, 13 Europe) from July 
2018 to October 2019. Primary efficacy end points were successful postprocedure angiographic revascularization 
(modified Thrombolysis in Cerebral Infarction ≥2b) and 90-day functional outcome (modified Rankin Scale score 0–2). 
The primary safety end point was 90-day all-cause mortality. An imaging core lab determined modified Thrombolysis 
in Cerebral Infarction scores, Alberta Stroke Program Early CT Scores, clot location, and occurrence of intracranial 
hemorrhage at 24 hours. Independent medical reviewers adjudicated safety end points.
RESULTS: Six hundred fifty patients were enrolled (median age 70 years, 54.0% female, 49.2% given intravenous recombinant 
tissue plasminogen activator before thrombectomy). Rate of modified Thrombolysis in Cerebral Infarction 2b to 3 postprocedure 
was 87.8% (95% CI, 85.3%–90.4%). First pass and postprocedure rates of modified Thrombolysis in Cerebral Infarction 2c 
to 3 were 41.5% and 66.2%, respectively. At 90 days, 55.8% (95% CI, 51.9%–59.7%) had modified Rankin Scale score 0 
to 2, and all-cause mortality was 15.5% (95% CI, 12.8%–18.3%).
CONCLUSIONS: Using Penumbra System for frontline mechanical thrombectomy treatment of patients with large vessel 
occlusion–acute ischemic stroke in a real-world setting was associated with angiographic, clinical, and safety outcomes that 
were comparable to prior randomized clinical trials with stringent site and operator selection criteria.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03464565.
GRAPHIC ABSTRACT: An online graphic abstract is available for this article.
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Mechanical thrombectomy (MT) is the current standard of care for large vessel occlusion–acute ischemic stroke (LVO-AIS) treatment.1,2 
Results from multiple randomized controlled trials 
support the safety and efficacy of MT.3–8 This may be 
related to improved patient selection and newer gen-
eration thrombectomy devices.
The American Heart/American Stroke Association 
2019 and the European Stroke Organization/European 
Society for Minimally Invasive Neurological Therapy 
2019 Guidelines agree that high-quality evidence exists 
to support the use of MT plus best medical management 
over best medical management alone in patients with 
anterior circulation LVO-AIS with an Alberta Stroke Pro-
gram Early CT Score (ASPECTS) ≥6 presenting within 
6 hours of onset. Both also agree that MT is reasonable 
and should be considered for patients with ASPECTS<6, 
or posterior circulation occlusions, but acknowledge the 
lack of high-quality evidence available for these less 
explored populations.1,2
The Penumbra System (Penumbra Inc, Alameda) is 
an MT system specifically designed to remove thrombus 
using aspiration.9–11 Several design and catheter size 
iterations have been made since the initial commercial 
launch and the Penumbra System was used in several 
trials, including ADAPT FAST (A Direct Aspiration First 
Pass Technique for Acute Stroke Thrombectomy),12 
ASTER (The Contact Aspiration vs Stent Retriever for 
Successful Revascularization),13 PROMISE (Prospec-
tive Multicenter Imaging Study for Evaluation of Chest 
Pain),14 the 3-dimensional (3D) Randomized Trial,15 and 
COMPASS (Cardiovascular Outcomes for People Using 
Anticoagulation Strategies)16—providing additional clini-
cal data supporting the Penumbra System’s performance. 
Citing results of COMPASS,16 ASTER,13 and the 3D Ran-
domized Trial,15 the American Heart/American Stroke 
Association guidelines endorse frontline aspiration 
thrombectomy as noninferior to stent retrievers.2 These 
trials had strict site selection criteria, enrollment criteria, 
and restricted patient population by anterior circulation 
LVO location,13,14,16 time from symptom onset,13–16 and 
eligibility-for or response-to intravenous thrombolytic 
therapy.15 Furthermore, several recent additions to the 
Penumbra System were not included in these prior trials.
This study, the COMPLETE (International Acute Isch-
emic Stroke Registry With the Penumbra System Aspira-
tion Including the 3D Revascularization Device) Registry, 
evaluated the generalizability of the Penumbra System’s 
performance in a real-world setting.
METHODS
COMPLETE was a global, prospective, multicenter, single-arm, 
postmarket, registry assessing the performance of the Penumbra 
System in an LVO-AIS patient population. Forty-two sites (29 
United States, 13 Europe) enrolled patients from July 2018 
through October 2019, and 90-day follow-up was completed in 
January 2020. The data that support the findings of this study are 
available from the corresponding author upon reasonable request.
Inclusion criteria were patient age ≥18 years, prestroke 
modified Rankin Scale (mRS) score 0 to 1, patient experiencing 
AIS secondary to intracranial LVO who is eligible for MT using 
Penumbra System, planned frontline treatment with Penumbra 
System, and signed informed consent per Institutional Review 
Board/Ethics Committee.
Exclusion criteria were any comorbid disease or condition 
expected to compromise survival or ability to complete follow-up 
assessments through 90 days and currently participating in an 
investigational (drug, device, etc) clinical trial that will confound 
registry end points. Patients in observational, natural history, or epi-
demiological studies not involving intervention remained eligible.
Investigators used routine clinical evaluations to determine 
patient eligibility. Advanced imaging was not required but permis-
sible per site standard of care. A screening and enrollment log of 
all MT eligible patients with LVO-AIS was maintained at each par-
ticipating hospital with reason(s) for exclusion recorded. Patients 
were considered enrolled once informed consent was obtained 
and Penumbra System was inserted into the body. Participating 
hospitals entered data into the Oracle InForm electronic data 
capture system (Oracle, Austin, TX). To ensure data accuracy and 
protocol compliance, the sponsor implemented risk-based moni-
toring. The RECORD (Reporting of Studies Conducted Using 
Observational Routinely-Collected Data) statement checklist and 
study flow diagram are available in the Data Supplement.17
Frontline treatment modality (direct aspiration only or aspira-
tion combined with a 3D Revascularization Device) was decided 
by the treating physician. Procedures were conducted in accor-
dance with routine care. Available devices included the MAX, 
ACE, and JET reperfusion catheters; the 3D Revascularization 
Device; and the Pump MAX, and ENGINE aspiration sources. 
The catheter distal inner dimensions ranged from 0.035” (0.89 
mm) to 0.072” (1.83 mm). The aspiration sources are designed 
to deliver and maintain a consistent vacuum (−29.2 in Hg or 
98.9 kPa for ENGINE).
The following predefined cohorts represent different 
patient populations and were reported separately: cohort A 
(anterior LVO with ASPECTS≥6), cohort B (anterior LVO with 
Nonstandard Abbreviations and Acronyms
AIS acute ischemic stroke
ASPECTS  Alberta Stroke Program Early CT 
Score
ECASS  European Cooperative Acute Stroke 
Study
ENT  Embolization in previously uninvolved 
or New Territories
LVO large vessel occlusion
mRS modified Rankin Scale
MT mechanical thrombectomy
mTICI  modified Thrombolysis in Cerebral 
Infarction
SAE serious adverse event
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ASPECTS<6), and cohort C (posterior LVO). All end point anal-
yses were conducted in cohort A. Exploratory analyses were 
conducted in cohorts B and C.
End Points
The primary efficacy end points were angiographic revascular-
ization of the occluded target vessel at immediate postproce-
dure as defined by modified Thrombolysis in Cerebral Infarction 
(mTICI) score ≥2b and functional subject outcome at 90 days 
postprocedure defined as mRS score 0 to 2. mTICI 2b was 
defined as substantial reperfusion with distal branch filling of 
≥50% of territory visualized. The primary safety end point was 
all-cause mortality at 90 days.
The secondary end points included incidence of device- and 
procedure-related serious adverse events (SAEs), occurrence 
of embolization in previously uninvolved or new territories (ENT) 
as seen on the final control angiogram at the end of procedure, 
occurrence of symptomatic intracranial hemorrhage (sICH) at 
24 hours, and time to revascularization.
Efforts were made to reduce the number of patients lost 
to follow-up. At a minimum, this included 3 attempts to make 
contact via telephone or email, and if unsuccessful, a letter from 
the investigator was sent via certified mail or other traceable 
methods to the patient’s last known address. Patients were 
considered lost to follow-up if these efforts failed. Assessments 
of mRS were performed per site standard of care. Other end 
point information is presented based on imaging core lab or 
independent medical reviewer assessments.
Study Committees
An independent imaging core lab reviewed pseudonymized angi-
ography for mTICI scores, preprocedure CT for ASPECTS, com-
puted tomography angiography for clot location, and 24-hour CT 
to assess hemorrhagic transformation using ECASS (European 
Cooperative Acute Stroke Study) classification.
Independent medical reviewers adjudicated all device-
related SAEs, neurovascular procedure–related SAEs, sICH 
within 24 hours, events of neurological deterioration, and any 
deaths that occurred throughout the registry. Neurological dete-
rioration was defined as a ≥4-point worsening of the National 
Institutes of Health Stroke Scale score from baseline, and sICH 
was defined as 24-hour evidence of an ECASS defined ICH 
associated with a ≥4-point worsening of the National Institutes 
of Health Stroke Scale score from baseline.
Institutional Review Board/Ethics Committees
The study and informed consent process were approved by the 
Institutional Review Board/Ethics Committee for each partici-
pating center before registry initiation. Informed consent was 
obtained for all enrolled patients per local Institutional Review 
Board/Ethics Committee requirements. See Data Supplement 
for a complete list of all Institutional Review Board/Ethics 
Committee. The informed consent process was consistent 
with the applicable elements of EN ISO14155, clinical inves-
tigation of medical devices for human subjects—good clinical 
practice and 21 Code of Federal Regulations Part 50 and 54. 
In the United States, for emergent cases where the patient 
was unable to provide consent and a legally authorized repre-
sentative was absent before the procedure, informed consent 
could be obtained within 2 calendar days. In Europe, informed 
consent was obtained for all cases before the procedure from 
the patient, next of kin, legally authorized representative, or 1 
or 2 independent physician(s); if informed consent could not 
be obtained directly from the patient before procedure, it was 
obtained again before discharge either from the patient or other 
authorized persons per local Ethics Committee requirements.
Statistical Analysis
Data were summarized using standard descriptive statistics 
(number of observations, mean, median, SD, and interquartile 
range for continuous variables, and counts and percentages 
for discrete variables). Statistical tests for continuous variables 
used the Wilcoxon Mann-Whitney rank-sum test and categori-
cal variables were tested using Fisher exact test. Two-sided 
Exact Clopper-Pearson CI are presented. All statistical tests 
are 2-tailed with a significance level of 0.05. Sensitivity analy-
ses were done using 3 imputation strategies for patients with 
missing primary efficacy end point data: poor outcome (mRS 
score 3–6), good outcome (mRS score 0–2), and multiple 
imputation. Poolability analysis with a hierarchical linear mixed 
model accounting for patient characteristics was performed. 
See Data Supplement for additional details. Analyses were 
conducted using SAS (SAS Institute, Cary, NC).
An estimated sample size of 650 was chosen for its abil-
ity to provide a sufficient level of precision to assess the 
Penumbra System and 3D Revascularization Device in the pre-
specified primary cohort A based on previously reported inci-
dence rates. Approximately 500 patients (≈77% of enrollment) 
were anticipated to be in cohort A. Assuming a postprocedure 
angiographic success rate of 85% (425/500), the expected 
binomial 2-sided 95% CI was (81.9%–88.1%). Assuming 10% 
attrition and a 90-day mRS success rate of 45% (202/450), 
the expected binomial 2-sided 95% CI was (40.3%–49.5%).
Approximately 100 patients (≈15% of enrollment) were 
anticipated to be in cohort B, and ≈50 patients (≈8% of enroll-
ment) were anticipated to be in cohort C.
RESULTS
Of the 1501 patients screened, 650 were enrolled (454 
United States, 196 Europe). A study flow diagram and 
screen failure details are available in the Data Supple-
ment. The completion rate through final follow-up was 
high (94.6%), and the attrition rate (5.4%) was better 
than the expected 10%. Of the 35 patients that did not 
complete the study, 5 withdrew consent, 2 were with-
drawn by a study investigator, 25 were lost to follow-up, 
and 3 did not complete for other reasons.
Baseline data are presented in Table 1. Median age 
was 70 years (range, 22–96 years), and 54% were 
female. Most patients (52.8%) were transferred from 
another hospital, and 49.2% received intravenous 
recombinant tissue-type plasminogen activator before 
thrombectomy. Strokes were witnessed, wakeup, or 
unwitnessed in 52.2%, 10.0%, and 37.8% of cases, 
respectively. Median time from onset to door was 193 
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Table 1. Baseline Characteristics and Procedural Data





Cohort C/posterior  
circulation (n=51)
Baseline demographics
 Female 54.0% (351/650) 56.8% (298/525) 44.4% (32/72) 39.2% (20/51)
 Age, y 70.0 [60.0–79.0] 71.0 [61.0–80.0] 66.0 [53.0–76.5] 66.0 [57.0–80.0]
 Race*
  Asian 2.9% (13/454) 2.5% (9/363) 3.8% (2/53) 5.4% (2/37)
  Black 13.4% (61/454) 12.7% (46/363) 13.2% (7/53) 18.9% (7/37)
  White 79.5% (361/454) 80.7% (293/363) 77.4% (41/53) 73.0% (27/37)
  Other 1.3% (6/454) 1.1% (4/363) 3.8% (2/53) 0.0% (0/37)
  Not reported 2.9% (13/454) 3.0% (11/363) 1.9% (1/53) 2.7% (1/37)
 Past medical history
  Previous ischemic stroke 14.9% (97/650) 15.0% (79/525) 13.9% (10/72) 15.7% (8/51)
  Previous hemorrhagic stroke 0.3% (2/650) 0.4% (2/525) 0.0% (0/72) 0.0% (0/51)
  Atrial fibrillation 33.4% (217/650) 35.4% (186/525) 19.4% (14/72) 31.4% (16/51)
  Cardiovascular/vascular disease 50.8% (330/650) 51.4% (270/525) 47.2% (34/72) 49.0% (25/51)
  Diabetes 23.7% (154/650) 23.0% (121/525) 22.2% (16/72) 31.4% (16/51)
  Hypertension 72.0% (468/650) 72.4% (380/525) 65.3% (47/72) 76.5% (39/51)
  Hyperlipidemia 42.3% (275/650) 42.1% (221/525) 41.7% (30/72) 45.1% (23/51)
  Renal failure 5.5% (36/650) 5.5% (29/525) 4.2% (3/72) 7.8% (4/51)
 Prestroke mRS score >1 0.6% (4/650) 0.8% (4/525) 0.0% (0/72) 0.0% (0/51)
Presentation
 Initial NIHSS 15.0 [9.0–20.0] (n=648) 14.0 [9.0–20.0] (n=524) 18.0 [15.5–22.0] (n=72) 12.0 [5.0–18.0] (n=50)
 Initial ASPECTS 8.0 [7.0–9.0] (n=597) 8.0 [7.0–9.0] (n=525) 4.0 [3.0–5.0] (n=72) N/A
 Initial pc-ASPECTS 9.0 [8.0–10.0] (n=49) N/A N/A 9.0 [8.0–10.0] (n=49)
 Site of vessel occlusion
  ICA 4.6% (30/650) 5.3% (28/525) 2.8% (2/72) N/A
  ICA-T 12.8% (83/650) 11.8% (62/525) 29.2% (21/72) N/A
  ACA 0.6% (4/650) 0.6% (3/525) 0.0% (0/72) N/A
  MCA, M1 55.2% (359/650) 59.8% (314/525) 62.5% (45/72) N/A
  MCA, M2 17.4% (113/650) 20.6% (108/525) 5.6% (4/72) N/A
  MCA, M3 1.4% (9/650) 1.7% (9/525) 0.0% (0/72) N/A
  MCA, M4 0.2% (1/650) 0.2% (1/525) 0.0% (0/72) N/A
  Vertebral 0.2% (1/650) N/A N/A 2.0% (1/51)
  Basilar, proximal 0.8% (5/650) N/A N/A 9.8% (5/51)
  Basilar, mid 1.4% (9/650) N/A N/A 17.6% (9/51)
  Basilar, terminus 2.9% (19/650) N/A N/A 37.3% (19/51)
  PCA 2.5% (16/650) N/A N/A 31.4% (16/51)
 Other, both PCA and proximal SCA 0.2% (1/650) N/A N/A 2.0% (1/51)
 Transferred from another hospital 52.8% (343/650) 51.8% (272/525) 58.3% (42/72) 56.9% (29/51)
 IV r-tPA administered 49.2% (320/650) 50.1% (263/525) 58.3% (42/72) 29.4% (15/51)
 Time of stroke symptom onset determination
  Witnessed 52.2% (338/648) 52.0% (272/523) 52.8% (38/72) 52.9% (27/51)
  Wake up 10.0% (65/648) 10.5% (55/523) 4.2% (3/72) 13.7% (7/51)
  Unwitnessed (time last seen well) 37.8% (245/648) 37.5% (196/523) 43.1% (31/72) 33.3% (17/51)








 Time from door to arterial puncture, min§ 68.0 [40.0–102.0] (n=629) 68.0 [41.0–102.0] (n=507) 59.5 [37.5–92.0] (n=72) 77.5 [43.0–109.5] (n=48)
Procedure
  Time from arterial puncture to mTICI 
2b–3 else final angiogram, min
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from door to puncture was 68 minutes (interquartile 
range, 40–102). Median ASPECTS was 8, and median 
posterior circulation ASPECTS was 9.
Most patients had an anterior circulation LVO (92.2%) 
and the remaining 7.8% had a posterior circulation LVO. 
Two patients with anterior circulation LVO were missing 
ASPECTS and, therefore, not assigned to any cohort. The 
most common anterior LVO locations were the M1 mid-
dle cerebral artery (59.9%), M2 middle cerebral artery 
(18.9%), and internal carotid artery terminus (13.9%). 
The most common posterior LVO locations were the bas-
ilar terminus (37.3%), posterior cerebral artery (31.4%), 
and middle portion of the basilar artery (17.6%).
Procedural data are available in Table 1. Frontline 
treatment was aspiration alone in 62.9% of cases and 
aspiration combined with the 3D Revascularization 
Device in 36.5% of cases. For frontline aspiration alone 
cases, the most common reperfusion catheters chosen 
were the ACE68 (43.5%) and the JET7 (37.9%). For 
frontline combined technique cases, the most common 
reperfusion catheters chosen were the JET7 (49.4%) 
and the ACE68 (26.2%). In 8 cases, the 3D Revascu-
larization Device was used with a non-Penumbra cath-
eter as frontline treatment. Median time from puncture to 
mTICI 2b to 3 reperfusion was 26 minutes (interquartile 
range, 15–40). Additional device use details and prepro-
cedural and procedural time metrics are available in the 
Data Supplement.
Outcomes—All Patients
Outcome information is available in Table 2. Successful 
revascularization (mTICI 2b–3) was achieved in 56.8% 
(368/648) of cases postfirst pass, 76.4% (496/649) 
post-Penumbra System, and 87.8% (571/650 [95% 
CI, 85.3%–90.4%]) postprocedure. Functional outcome 
(mRS score 0–2) at 90 days was 55.8% (342/613 
[95% CI, 51.9%–59.7%]). Figure shows a full distribu-
tion of mRS scores at 90 days.
Vessel perforation occurred in 0.3% (2/650) of cases, 
vessel dissection in 0.9% (6/650), and ENT in 2.8% 
(18/650). Device-related SAE within 24 hours occurred 
in 0.6% (4/650) of cases, procedure-related SAE within 
24 hours in 5.8% (38/650), neurological deterioration 
in 9.1% (59/650), and sICH within 24 hours in 3.8% 
(25/650). Overall, 36.5% (237/650) of patients experi-
enced any ICH within 24 hours. Using ECASS classifica-
tion (Table 3), rate of PH-2 was 3.1% (20/650), and rate 
of SAH was 8.2% (53/650). All-cause mortality at 90 
days was 15.5% (101/650 [95% CI, 12.8%–18.3%]).
Outcomes—Cohort A (Anterior LVO With 
ASPECTS≥6)
For cohort A, mTICI 2b to 3 was achieved in 56.4% 
(295/523) of cases postfirst pass, 75.2% (394/524) 
post-Penumbra System, and 87.4% (459/525 [95% CI, 
84.6%–90.3%]) postprocedure. At 90 days, mRS score 
0 to 2 was 59.6% (295/495 [95% CI, 55.3%–63.9%]).
Vessel perforation occurred in 0.4% (2/525) of cases, 
vessel dissection in 1.0% (5/525), and ENT in 2.5% 
(13/525). Device-related SAE within 24 hours occurred 
in 0.6% (3/525) of cases, procedure-related SAE within 
24 hours in 5.1% (27/525), neurological deterioration 
in 8.0% (42/525), and sICH within 24 hours in 3.8% 
(20/525). Overall, 35.6% (187/525) of cohort A expe-
rienced any ICH within 24 hours. Using ECASS classifi-
cation (Table 3), rate of PH-2 was 3.2% (17/525), and 
rate of SAH was 9.0% (47/525). All-cause mortality at 
90 days was 14.1% (74/525 [95% CI, 11.1%–17.1%]).
 First pass treatment modality
  Direct aspiration alone 62.9% (409/650) 63.0% (331/525) 59.7% (43/72) 64.7% (33/51)
   Direct aspiration with penumbra 3D 
Revascularization Device
36.5% (237/650) 36.6% (192/525) 38.9% (28/72) 33.3% (17/51)
 Additional attempts on∥
  Target vessel 43.4% (282/650) 43.4% (228/525) 52.8% (38/72) 31.4% (16/51)
  Distal vasculature 8.2% (53/650) 7.2% (38/525) 15.3% (11/72) 7.8% (4/51)
  Proximal stenosis or tandem lesion 2.5% (16/650) 2.1% (11/525) 6.9% (5/72) 0.0% (0/51)
  Intracranial carotid artery disease 0.6% (4/650) 0.8% (4/525) 0.0% (0/72) 0.0% (0/51)
% (n/N), median [IQR], mean (SD). 3D indicates 3-dimensional; ACA, anterior cerebral artery; ASPECTS, Alberta Stroke Program Early CT Score; ICA, internal carotid 
artery; ICA-T, ICA-Terminus; IQR, interquartile range; IV r-tPA, intravenous recombinant tissue-type plasminogen activator; MCA, middle cerebral artery; mRS, modified 
Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; N/A, not applicable; NIHSS, National Institutes of Health Stroke Scale; PCA, posterior cerebral artery; 
pc-ASPECTS, posterior circulation–ASPECTS; and SCA, superior cerebellar artery.
*Collected only for patients in the United States.
†Patients with onset time unknown are excluded from analysis.
‡Patients already admitted to hospital before stroke are assigned an onset to admission time of 0 min.
§Patients with prestroke admission at the hospital are excluded from the analysis.
∥Multiple responses allowed for each patient.
Table 1. Continued
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Outcomes—Cohort B (Anterior LVO With 
ASPECTS<6)
For cohort B, mTICI 2b to 3 was achieved in 47.2% 
(34/72) of cases postfirst pass, 77.8% (56/72) post-
Penumbra System, and 87.5% (63/72 [95% CI, 79.9%–
95.1%]) postprocedure. At 90 days, mRS score 0 to 2 
was 32.3% (21/65 [95% CI, 20.9%–43.7%]).
Vessel perforation occurred in 0.0% (0/72) of 
cases, vessel dissection in 0.0% (0/72), and ENT in 
6.9% (5/72). Device-related SAE within 24 hours 
occurred in 1.4% (1/72) of cases, procedure-related 
SAE within 24 hours in 9.7% (7/72), neurologi-
cal deterioration in 16.7% (12/72), and sICH within 
24 hours in 5.6% (4/72). Overall, 54.2% (39/72) of 
cohort B experienced any ICH within 24 hours. Using 
ECASS classification (Table 3), rate of PH-2 was 4.2% 
(3/72), and rate of SAH was 4.2% (3/72). All-cause 
mortality at 90 days was 25.0% (18/72 [95% CI, 
15.0%–35.0%]).
Outcomes—Cohort C (Posterior LVO)
For cohort C, mTICI 2b to 3 was achieved in 72.5% 
(37/51) of cases postfirst pass, 86.3% (44/51) post-
Penumbra System, and 92.2% (47/51 [95% CI, 84.8%–
99.5%]) postprocedure. At 90 days, mRS score 0 to 2 
was 49.0% (25/51 [95% CI, 35.3%–62.7%]).
Table 2. Outcomes
 All subjects (N=650)
Cohort A/anterior circulation 
ASPECTS≥6 (n=525)
Cohort B/anterior circulation 
ASPECTS<6 (n=72)
Cohort C/posterior  
circulation (n=51)
mTICI 2b–3 postfirst pass* 56.8% (368/648) 56.4% (295/523) 47.2% (34/72) 72.5% (37/51)
mTICI 2c–3 postfirst pass* 41.5% (269/648) 40.5% (212/523) 33.3% (24/72) 60.8% (31/51)
mTICI 3 postfirst pass* 31.8% (206/648) 30.6% (160/523) 22.2% (16/72) 56.9% (29/51)
mTICI 2b–3 post-Penumbra 
System
76.4% (496/649) 75.2% (394/524) 77.8% (56/72) 86.3% (44/51)
mTICI 2b–3 postprocedure 87.8% (571/650)  
(85.3%–90.4%)
87.4% (459/525)  
(84.6%–90.3%)
87.5% (63/72)  
(79.9%–95.1%)
92.2% (47/51)  
(84.8%–99.5%)
mTICI 2c–3 postprocedure 66.2% (430/650) 65.9% (346/525) 61.1% (44/72) 74.5% (38/51)
Safety outcomes
  All-cause mortality at 90 
days
15.5% (101/650)  
(12.8%–18.3%)
14.1% (74/525)  
(11.1%–17.1%)
25.0% (18/72)  
(15.0%–35.0%)
17.6% (9/51)  
(7.2%–28.1%)
 ENT 2.8% (18/650) (1.5%–4.0%) 2.5% (13/525) (1.1%–3.8%) 6.9% (5/72) (1.1%–12.8%) 0.0% (0/51) (0.0%–0.0%)
 Neurological Deterioration 9.1% (59/650) 8.0% (42/525) 16.7% (12/72) 9.8% (5/51)
 sICH within 24 h 3.8% (25/650) (2.4%–5.3%) 3.8% (20/525) (2.2%–5.4%) 5.6% (4/72) (0.3%–10.8%) 2.0% (1/51) (0.0%–5.8%)
 Vessel perforation 0.3% (2/650) (0.0%–0.7%) 0.4% (2/525) (0.0%–0.9%) 0.0% (0/72) (0.0%–0.0%) 0.0% (0/51) (0.0%–0.0%)
 Vessel dissection 0.9% (6/650) (0.2%–1.7%) 1.0% (5/525) (0.1%–1.8%) 0.0% (0/72) (0.0%–0.0%) 2.0% (1/51) (0.0%–5.8%)
  Device-related SAE, within 
24 h
0.6% (4/650) (0.0%–1.2%) 0.6% (3/525) (0.0%–1.2%) 1.4% (1/72) (0.0%–4.1%) 0.0% (0/51) (0.0%–0.0%)
 Device-related SAE, all 1.1% (7/650) (0.3%–1.9%) 0.8% (4/525) (0.0%–1.5%) 2.8% (2/72) (0.0%–6.6%) 2.0% (1/51) (0.0%–5.8%)
  Procedure-related SAE, 
within 24 h
5.8% (38/650) (4.0%–7.6%) 5.1% (27/525) (3.3%–7.0%) 9.7% (7/72) (2.9%–16.6%) 7.8% (4/51) (0.5%–15.2%)
 Procedure-related SAE, all 7.7% (50/650) (5.6%–9.7%) 7.0% (37/525) (4.9%–9.2%) 11.1% (8/72) (3.9%–18.4%) 9.8% (5/51) (1.6%–18.0%)
  Device- or procedure-
related SAE, within 24 h
5.8% (38/650) (4.0%–7.6%) 5.1% (27/525) (3.3%–7.0%) 9.7% (7/72) (2.9%–16.6%) 7.8% (4/51) (0.5%–15.2%)
  Device- or procedure-
related SAE, all
8.0% (52/650) (5.9%–10.1%) 7.2% (38/525) (5.0%–9.5%) 11.1% (8/72) (3.9%–18.4%) 11.8% (6/51) (2.9%–20.6%)
mRS score 0–2 progression
 Day 7–10 or discharge 41.7% (257/616) 45.2% (225/498) 14.7% (10/68) 43.8% (21/48)
 Day 30 49.8% (308/618) 54.3% (271/499) 23.9% (16/67) 42.0% (21/50)
 Day 90 55.8% (342/613)  
(51.9%–59.7%)
59.6% (295/495)  
(55.3%–63.9%)
32.3% (21/65)  
(20.9%–43.7%)
49.0% (25/51)  
(35.3%–62.7%)
NIHSS progression
 At 24 h 6.0 [2.0–15.0] (n=626) 6.0 [2.0–15.0] (n=507) 15.0 [8.0–22.0] (n=69) 4.0 [1.0–10.0] (n=48)
 Day 7–10 or discharge 3.0 [1.0–11.0] (n=614) 3.0 [0.0–10.0] (n=500) 12.5 [6.0–20.0] (n=68) 2.0 [0.0–4.5] (n=44)
% (n/N), % (n/N) (95% CI), median [IQR]. ASPECTS indicates Alberta Stroke Program Early CT Score; ENT, embolization in previously uninvolved or new territories; 
IQR, interquartile range; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; SAE, seri-
ous adverse event; and sICH, symptomatic intracranial hemorrhage.
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Vessel perforation occurred in 0.0% (0/51) of cases, 
vessel dissection in 2.0% (1/51), and ENT in 0.0% 
(0/51). Device-related SAE within 24 hours occurred 
in 0.0% (0/51) of cases, procedure-related SAE within 
24 hours in 7.8% (4/51), neurological deterioration in 
9.8% (5/51), and sICH within 24 hours in 2.0% (1/51). 
Overall, 19.6% (10/51) of cohort C experienced any ICH 
within 24 hours. Using ECASS classification (Table 3), 
rate of PH-2 was 0.0% (0/51), and rate of SAH was 
5.9% (3/51). All-cause mortality at 90 days was 17.6% 
(9/51 [95% CI, 7.2%–28.1%]).
DISCUSSION
To date, COMPLETE is the largest prospective study 
evaluating the real-world experience of using the Pen-
umbra System as the frontline MT approach in patients 
with LVO-AIS. In the anterior circulation LVO with 
ASPECTS≥6 cohort, the study demonstrated a postpro-
cedure revascularization success (mTICI 2b–3) rate of 
87.4% and an excellent first pass effect (after a single 
attempt with the Penumbra System, mTICI 2b to 3, mTICI 
2c to 3, and mTICI 3 was achieved in 56.4%, 40.5%, 
and 30.6% of patients, respectively). These angiographic 
results translated to a high proportion of patients with 
good clinical outcomes, with close to 60% of patients 
regaining functional independence at 90 days. Safety 
results demonstrated low rates of sICH (3.8%) and all-
cause mortality (14.1%). The observed postprocedure 
mTICI 2b to 3 rate (87.4% [95% CI, 84.6 %–90.3%]) 
fell within the range of our predetermined expected rate 
(85% [95% CI, 81.9%–88.1%]). The 95% CI of 84.6% 
to 90.3% is consistent with the 85% to 90% target 
effect mentioned by Lin and Saver18 in their publication 
regarding minimal clinically important difference for sub-
stantial reperfusion. The observed 90-day mRS score 0 
to 2 success rate (59.6% [95% CI, 55.3%–63.9%]) was 
better than expected (predetermined expected rate was 
45% [95% CI, 40.3%–49.5%]).
Real-World COMPLETE Registry Versus 
Randomized Clinical Trials
To accurately capture real-world performance, COMPLETE 
involved a large number of sites and a range of operator 
of experience levels. Prior randomized clinical trials, COM-
PASS and ASTER, selected high-volume sites with experi-
enced operators.13,16 In COMPASS, the rates of mTICI 2b 
to 3 at end of procedure, functional independence (mRS 
score 0–2), sICH, and all-cause mortality were 92%, 52%, 
6%, and 22%, respectively.16 In ASTER, the rates of mTICI 
2b to 3 at end of procedure, functional independence 
(mRS score 0–2), sICH, and all-cause mortality were 
85%, 45%, 5%, and 19%, respectively.13 As comparison, 
in the anterior circulation LVO with ASPECTS≥6 cohort of 
our COMPLETE real-world registry, the rates of mTICI 2b 
to 3 at end of procedure, functional independence (mRS 
score 0–2), sICH, and all-cause mortality were 87%, 60%, 
4%, and 14%, respectively. Despite including a wide range 
of clinical site and operator experience levels, the COM-
PLETE registry’s angiographic, functional independence, 
and safety outcomes were comparable to, or better than 
prior randomized trials. Additionally, both COMPASS and 
ASTER restricted enrollment to patients presenting within 
6 hours of symptom onset whereas COMPLETE did not 
restrict by time from symptom onset.13,16
Figure. Distribution of the modified Rankin Scale (mRS) scores at 90 d for the full study population (all patients) and the pre-
specified cohorts (Cohort A, ASPECTS [Alberta Stroke Program Early CT Score] 6-10; cohort B, ASPECTS 0-5, large core infarct; 
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Several factors contributed to the excellent angio-
graphic, functional, and safety outcomes found in our 
COMPLETE registry. Technical advances over the years 
have made aspiration catheters more trackable and eas-
ier to navigate. The wide availability of larger inner diame-
ter aspiration catheters (eg, JET 7) and newer generation 
pump (eg, ENGINE pump) improves the efficiency of 
aspiration and may have led to the high rate of success-
ful revascularization seen in COMPLETE. Additionally, 
the functional independence rate (59.6%) is one of the 
highest reported in the literature for patients with ante-
rior circulation LVO with ASPECTS≥6 treated frontline 
with Penumbra System. This can be partially explained 
by the high rate of first pass successful revasculariza-
tion to mTICI 2b to 3 (56.4%) and partially explained by 
better patient selection. Since the series of positive MT 
trials,3–8 advanced imaging to screen patients is more 
prevalent,6,19 and many stroke teams have established 
clear patient selection criteria for MT. These improve-
ments potentially contributed to the higher rate of good 
clinical outcome, lower rate of sICH, and lower rate of 
all-cause mortality found in this study.
Additional Subgroup Outcomes in the 
Complete Real-World Registry
Despite the large sample size (N=650), the current 
study had few patients enrolled with anterior circulation 
LVO and ASPECTS<6 (n=72), or posterior circulation 
LVO (n=51). These cohorts yielded several unexpected 
observations. Functional independence at 90 days was 
better than expected (32.3% for low ASPECTS, and 
49.0% for posterior LVO). These rates are numerically 
higher than those reported by Kaesmacher et al20 in a 
recent multicenter pooled analysis of 237 patients with 
low ASPECTS and those reported by Deb-Chatterji et 
al21 in a subgroup analysis of 152 patients from the Ger-
man Stroke Registry–Endovascular Treatment with low 
ASPECTS. In the Kaesmacher et al20 and Deb-Chatterji 
et al21 studies, functional independence was achieved 
in 24.6% of patients and 21.7% of patients, respec-
tively. Additionally, our study’s low ASPECTS cohort had 
favorable rates of sICH (5.6%) and all-cause mortality 
(25.0%) when compared with Kaesmacher et al20 (sICH 
7.2%, all-cause mortality 40.1%) and Deb-Chatterji et 
al21 (sICH not reported, all-cause mortality 44.7%).
There are limited prospective independently adjudi-
cated data involving exclusively Penumbra System as 
frontline therapy on posterior circulation LVOs. In our 
cohort, we had a better than expected rate of functional 
independence at 90 days (49.0%) and low rates of sICH 
(2.0%) and all-cause mortality at 90 days (17.6%). This 
compares favorably to a recent systematic review of pos-
terior circulation LVO MT treatment which demonstrated 
38% favorable outcomes at 90 days and 30% mortality.22
The high rate of successful revascularization achieved 
in COMPLETE’s posterior circulation cohort (92.2% 
mTICI 2b–3 postprocedure and first pass mTICI 2b–3, 
2c–3, and 3 of 72.5%, 60.8%, and 56.9%, respectively, 
versus 56.4%, 40.5%, and 30.6%, respectively, in the 
anterior circulation LVO with ASPECTS≥6 cohort) is an 
important finding that warrants further investigation.
Strengths and Limitations
Limitations of the COMPLETE registry include the lack 
of a randomized comparison group, the ability to enroll 
emergent cases after the procedure (potentially biasing 
Table 3. Intracranial Hemorrhage Within 24 Hours, ECASS Classification
Intracranial hemor-
rhage by ECASS 
classification All subjects (N=650)
Cohort A/anterior circulation 
ASPECTS≥6 (n=525)
Cohort B/anterior circulation 
ASPECTS<6 (n=72)
Cohort C/posterior circulation 
(n=51)
Total intracranial hem-
orrhage within 24 h*
36.5% (237/650)  
(32.8%–40.2%)
35.6% (187/525)  
(31.5%–39.7%)
54.2% (39/72)  
(42.7%–65.7%)
19.6% (10/51)  
(8.7%–30.5%)
IPH 31.4% (204/650)  
(27.8%–35.0%)
29.9% (157/525)  
(26.0%–33.8%)
54.2% (39/72)  
(42.7%–65.7%)
13.7% (7/51)  
(4.3%–23.2%)
 HI-1 8.5% (55/650) (6.3%–10.6%) 8.6% (45/525) (6.2%–11.0%) 9.7% (7/72) (2.9%–16.6%) 3.9% (2/51) (0.0%–9.2%)
 HI-2 15.1% (98/650) (12.3%–17.8%) 13.5% (71/525) (10.6%–16.4%) 33.3% (24/72) (22.4%–44.2%) 5.9% (3/51) (0.0%–12.3%)
 PH-1 5.2% (34/650) (3.5%–6.9%) 5.1% (27/525) (3.3%–7.0%) 6.9% (5/72) (1.1%–12.8%) 3.9% (2/51) (0.0%–9.2%)
 PH-2 3.1% (20/650) (1.7%–4.4%) 3.2% (17/525) (1.7%–4.8%) 4.2% (3/72) (0.0%–8.8%) 0.0% (0/51) (0.0%–0.0%)
IVH 1.8% (12/650) (0.8%–2.9%) 2.1% (11/525) (0.9%–3.3%) 1.4% (1/72) (0.0%–4.1%) 0.0% (0/51) (0.0%–0.0%)
RIH 0.5% (3/650) (0.0%–1.0%) 0.4% (2/525) (0.0%–0.9%) 1.4% (1/72) (0.0%–4.1%) 0.0% (0/51) (0.0%–0.0%)
SAH 8.2% (53/650) (6.1%–10.3%) 9.0% (47/525) (6.5%–11.4%) 4.2% (3/72) (0.0%–8.8%) 5.9% (3/51) (0.0%–12.3%)
SDH 0.0% (0/650) (0.0%–0.5%) 0.0% (0/525) (0.0%–0.0%) 0.0% (0/72) (0.0%–0.0%) 0.0% (0/51) (0.0%–0.0%)
EDH 0.0% (0/650) (0.0%–0.5%) 0.0% (0/525) (0.0%–0.0%) 0.0% (0/72) (0.0%–0.0%) 0.0% (0/51) (0.0%–0.0%)
% (n/N) (95% CI). ASPECTS indicates Alberta Stroke Program Early CT Score; ECASS, European Cooperative Acute Stroke Study; EDH, epidural hematoma; HI, 
hemorrhagic infarction; ICH, intracranial hemorrhage; IPH, intraparenchymal hemorrhage; IVH, intraventricular hemorrhage; PH, parenchymal hematoma; RIH, any intra-
parenchymal hemorrhage remote from the infarcted tissue; SAH, subarachnoid hemorrhage; and SDH, subdural hematoma.
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toward better outcomes as surrogates of patients suf-
fering severe strokes may be less willing to consent to 
participate), and the absence of an independent cer-
tified assessor to evaluate mRS outcomes. Addition-
ally, not all consecutive patients were enrolled (eg, if 
informed consent was not obtained within the prespeci-
fied timeframe or if a patient declined to participate). 
Strengths of the COMPLETE registry include the pro-
spective nature, the large sample size, the use of an 
imaging core lab and independent medical reviewers, 
and the inclusion of a variety of sites and operator 
experience levels to more accurately reflect real-world 
clinical practice.
Conclusions
The COMPLETE registry found that use of the Penum-
bra System for frontline MT treatment of patients with 
LVO-AIS in a real-world setting was associated with 
angiographic, clinical, and safety outcomes that were 
comparable to prior randomized clinical trials that utilized 
stringent site and operator selection criteria.
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